Skip to main content
SpringerLink
Log in

Biologic therapy for inflammatory bowel disease comes of age

  • Clinical Trials Report
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.

    Article  PubMed  CAS  Google Scholar 

  2. Hanauer SB, Wagner CL, Bala M, et al.: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004, 2:542–553.

    Article  PubMed  CAS  Google Scholar 

  3. Wong M, Ziring D, Korin Y, et al.: TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol 2008, 126:121–136.

    Article  PubMed  CAS  Google Scholar 

  4. Vermeire S, Noman M, Van Assche G, et al.: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 2007, 56:1226–1231.

    Article  PubMed  CAS  Google Scholar 

  5. Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007, 132:52–65.

    Article  PubMed  CAS  Google Scholar 

  6. Sandborn WJ, Feagan BG, Stoinov S, et al.: Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007, 357:228–238.

    Article  PubMed  CAS  Google Scholar 

  7. Toruner M, Loftus EV Jr, Harmsen WS, et al.: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929–936.

    Article  PubMed  Google Scholar 

  8. Hanauer SB: Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: Is the synergy worth the risk? Gut 2007, 56:1181–1183.

    Article  PubMed  CAS  Google Scholar 

  9. Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004, 126:402–413.

    Article  PubMed  CAS  Google Scholar 

  10. Kandiel A, Fraser AG, Korelitz BI, et al.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121–1125.

    Article  PubMed  CAS  Google Scholar 

  11. Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000, 119:895–902.

    Article  PubMed  CAS  Google Scholar 

  12. van der Kooij SM, Allaart CF, Dijkmans BA, Breedveld FC: Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:287–294.

    Article  PubMed  Google Scholar 

  13. Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054–1061.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Stephen B. Hanauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanauer, S.B. Biologic therapy for inflammatory bowel disease comes of age. Curr Gastroenterol Rep 10, 565–567 (2008). https://doi.org/10.1007/s11894-008-0103-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-008-0103-y

Keywords

Search

Navigation